Medical/Pharmaceuticals APAC News & Press Release Distribution

YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...

2023-08-16 05:00 2482

CStone Pharmaceuticals Reports 2023 Interim Results and Updates

* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross profit margin improved from 47% to 59%. * Healthy fin...

2023-08-15 22:33 3147

Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)

SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...

2023-08-15 20:19 1720

Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM

Eighteen of the top 20 biopharmas standardize with Veeva to build meaningful customer relationships SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 18 of the top 20 biopharmas inAsia Pacific are using Veeva CRM

2023-08-15 09:00 2472

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...

2023-08-14 21:30 1666

UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency

HONG KONG, Aug. 14, 2023 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP " or the "Group", stock code: 722.HK) is pleased to announce the signing of a memorandum of understanding (MOU) withImsight Technology Company Limited, specialised in providing artificial intelligence (AI) medical imag...

2023-08-14 15:45 1902

UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency

Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint

CHENGDU, China, Aug. 14, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III ...

2023-08-14 12:50 3095

Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a$1M contract spanning two years (HHSF223018186...

2023-08-11 21:14 3033

Move Aside Anti-Ageing, It's Age Reversal We're Talking Now

SINGAPORE, Aug. 11, 2023 /PRNewswire/ -- In the realm of medical progress, the horizon extends far beyond the battle against diseases. Now, the concept of "age reversal" — not merely slowing down or halting ageing — stands as a tangible reality. However, the validity and accuracy of ageing measur...

2023-08-11 13:49 1815

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...

2023-08-11 11:14 1735

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...

2023-08-11 08:00 2518

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...

2023-08-11 07:18 1772

YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023

GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-08-11 04:30 4588

LyondellBasell Awarded the 2023 Global Medical Plastics Company of the Year by Frost & Sullivan

LyondellBasell is among the top three global polyolefin manufacturers in terms of capacity and sustainable solutions, catering to multiple industries, including pharmaceuticals and medical devices. SAN ANTONIO, Aug. 10, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the medical plasti...

2023-08-10 19:00 1648

AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endpoint, p...

2023-08-10 15:49 3984

Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]

* First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] — one of the leading causes of death inHong Kong[4] — has been approved by Hong Kong Department of Health inApril 2023 and is now available in Hong ...

2023-08-10 14:15 1560

Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]

APRIL Group partners the Indonesian Ministry of Health to elevate primary healthcare levels in Riau province

SINGAPORE, Aug. 10, 2023 /PRNewswire/ -- The Indonesian Ministry of Health (Kemenkes) and Asia Pacific Resources International Limited (APRIL) Group signed a Memorandum of Understanding (MOU) on25 July 2023 at PT. RAPP (Riau Andalan Pulp and Paper) facility - a business unit of APRIL Group. For ...

2023-08-10 12:43 1556

Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting

SUZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that posters to highlight the company's core pipeline products, PD-L1/CTLA-4 bispecific antibody KN046 and HER2 bispecific antibody KN026, will beannounced at the 2023 European Society for Medical Oncol...

2023-08-10 09:02 2405

Clarivate Launches Enhanced Search Powered by Generative Artificial Intelligence

Latest iteration of patent pending platform enables life sciences and pharmaceutical companies to access insights from billions of proprietary data points LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they c...

2023-08-09 15:00 1555

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that...

2023-08-09 13:00 2618